Observing Health and Experiences of Females with Cystic Fibrosis During Pregnancy and Early Parenthood, and Follow-up of Their Children
Led by Royal Brompton & Harefield NHS Foundation Trust · Updated on 2025-10-01
60
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the physical, nutritional, pulmonary, and mental health of females with cystic fibrosis CF who are planning pregnancy, are pregnant, or in early parenthood. They are also examining the health of their children from infancy through early childhood to see if new screening or care methods should be included in clinical guidelines. This observational study focuses on the impact of pregnancy and parenthood in the era of CFTR modulators, treatments that target the cause of CF.
The study, called MATRIARCHCF, includes three related sub-studies Mama follows females with CF aged 16 or older who are planning pregnancy or pregnant, involving up to eight visits with tests like blood work, lung function, imaging, and interviews. Mini enrolls biological offspring from birth to age two, with up to four visits including blood tests, sweat tests, and brain ultrasounds. Midi studies children aged three to six with up to two visits involving lung function tests and lung MRI. The study does not provide or change treatments but monitors health through these investigations.
Participants will attend multiple visits for physical and psychological assessments, including lung function, imaging, and blood tests for mothers, and various tests for children depending on their age group. Researchers will measure outcomes such as lung function changes, pulmonary complications during pregnancy, premature deliveries, liver dysfunction, congenital abnormalities, and CF diagnoses in children. The study aims to gather detailed health information over several years without altering clinical care, lasting up to three years for some outcomes.
CONDITIONS
Brief Title
A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring
Research Team
A
Amy Downes
I
Idan Bokobza
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Written informed consent obtained from participant or legal guardian
Under the care of Royal Brompton Hospital CF Reproductive and Maternal Health Service (Mama sub-study)
Age 16 years or above at time of recruitment (Mama sub-study)
Confirmed diagnosis of cystic fibrosis (Mama sub-study)
Planning a pregnancy or pregnant at time of recruitment (Mama sub-study)
Ability to adhere to required visits and investigations
Infants with one biological parent diagnosed with cystic fibrosis under care of Royal Brompton Hospital Adult CF Service, less than 12 months old at first visit (Mini sub-study)
Children aged 3 to 6 years with one biological parent diagnosed with cystic fibrosis under care of Royal Brompton Hospital Adult CF Service (Midi sub-study)
You will not qualify if you...
Any significant health condition causing inability to comply with study protocol (Mama sub-study)
History of lung transplantation (Mama sub-study)
Legal guardian unable to provide consent (Mini and Midi sub-studies)
Mother has significant comorbidities unrelated to cystic fibrosis that could affect infant outcomes (Mini sub-study)
Significant health condition known to affect lung function or imaging (Midi sub-study)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Monitoring for Pregnant Females with Cystic Fibrosis (Mama)
Duration - Up to 24 months
Participants who are pregnant or planning a pregnancy are observed to understand the impact of pregnancy and early parenthood on their physical and psychological health.
8 visits including blood tests, lung function, imaging, and interviews
Monitoring of Infants Aged 0-24 Months (Mini)
Duration - Up to 24 months
Biological offspring of people with cystic fibrosis from birth to age two are observed to assess health outcomes in the short term.
Up to 4 visits including blood tests, sweat tests, and brain ultrasound
Monitoring of Children Aged 3-6 Years (Midi)
Duration - Up to 2 visits
Children aged three to six with one biological parent who has cystic fibrosis are observed to assess longer-term health outcomes.
Up to 2 visits including lung function testing and lung MRI
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Prediction Model Study for Pregnancy Outcomes in Women Affected by Aplastic Anemia
A Repository to Study Host-Microbiome Interactions in Health and Disease
Comparing Video and Direct Laryngoscopy for Intubating Newborn Babies
A Randomized Study to Improve First-Attempt Success and Safety
Validating the Enlighten Device to Predict Postpartum Depression Using At-Home Blood and Saliva Samples in Pregnant Women
Observing Health and Experiences of Females with Cystic Fibrosis During Pregnancy and Early Parenthood, and Follow-up of Their Children
Evaluating Digital Support and Packaging Effects on Multiple Micronutrient Supplement Use Among Pregnant Women in Lombok Island
Study of Self-Help Acceptance and Commitment Therapy Toolkit for Adults with Cystic Fibrosis to Reduce Anxiety and Depression and Improve Well-being
Advanced Fetal Imaging Study Using New MRI Technology for Pregnant Women
Testing Specialized MRI Coils and Techniques to Improve Fetal Imaging Quality
Study to Evaluate the Accuracy of the T-ACE Self-report for Detecting High-Risk Alcohol Use During Pregnancy Compared to a Blood Test
Study of an Agricultural Support Program to Improve Health and Nutrition for Pregnant Women and Their Babies in Kenya
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Maternal, Infant, Reproductive and Child Health in Cystic Fibrosis (MATRIARCH_CF): a prospective, observational study to evaluate pregnancy and parenthood in females with cystic fibrosis and health of the offspring in the CFTR-modulator era.